Effectiveness of Pharmacokinetic-Guided Hydroxyurea Dose Individualization in Patients with Sickle Cell Anemia: A Mini-Review

Effectiveness of Pharmacokinetic-Guided Hydroxyurea Dose Individualization in Patients with Sickle Cell Anemia: A Mini-Review

Inconsistent therapeutic responses have been observed among patients with sickle cell anemia (SCA) undergoing hydroxyurea (HU) following the adoption of the standardized protocol. Moreover, this treatment regimen necessitates a prolonged period to reach the maximum tolerated dose in which beneficial...

Full description

Bibliographic Details
Main Authors:	Joelma Santana dos Santos Neres, Sètondji Cocou Modeste Alexandre Yahouédéhou, Marilda Souza Goncalves
Format:	Article
Language:	English
Published:	MDPI AG 2023-06-01
Series:	Pharmaceuticals
Subjects:	sickle cell anemia hydroxyurea personalized dose pharmacokinetics profile
Online Access:	https://www.mdpi.com/1424-8247/16/6/857

Similar Items

Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia
by: Emily R. Meier, et al.
Published: (2020-11-01)

Evaluation of pediatric hydroxyurea prescriptions for patients with sickle cell disease
by: Fernanda Alice Tanimoto Duque, et al.
Published: (2022-11-01)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
by: Lidiane de Souza Torres, et al.
Published: (2012-01-01)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
by: Lidiane de Souza Torres, et al.
Published: (2012-01-01)

Hydroxyurea treatment for adult sickle cell anemia patients in Kinshasa
by: Paul Lumbala Kabuyi, et al.
Published: (2023-08-01)

Hydroxyurea pharmacokinetics and precision dosing in low-resource settings
by: Luke R. Smart, et al.
Published: (2023-06-01)

Sickle Cell Anemia: Variants in the CYP2D6, CAT, and SLC14A1 Genes Are Associated With Improved Hydroxyurea Response
by: Sètondji Cocou Modeste Alexandre Yahouédéhou, et al.
Published: (2020-09-01)

Minimal doses of hydroxyurea for sickle cell disease
by: C.S.P. Lima, et al.
Published: (1997-08-01)

Patients with sickle cell disease taking hydroxyurea in the Hemocentro Regional de Montes Claros
by: Fernanda Kelle de Souza Santos, et al.
Published: (2011-01-01)

Clinical and laboratory profile of patients with sickle cell anemia
by: Phelipe Gabriel dos Santos Sant'Ana, et al.

Effects of hydroxyurea on cytotoxicity, inflammation and oxidative stress markers in neutrophils of patients with sickle cell anemia: dose-effect relationship
by: Alano Martins Pedrosa, et al.
Published: (2021-10-01)

Incidence of avascular necrosis in patients with sickle cell anemia received hydroxyurea and blood transfusion: a comparative study
by: Asmaa Hassan Khudhair, et al.
Published: (2025-12-01)

Influence of hydroxyurea on tubular phosphate handling in sickle cell nephropathy
by: Gabriela Araujo de Abreu, et al.
Published: (2024-11-01)

Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatment
by: Fabia Neves, et al.
Published: (2012-01-01)

Eficácia e toxicidade da hidroxiuréia em crianças com anemia falciforme Effectiveness and toxicity of hydroxyurea in children with sickle cell anemia
by: Michelle C. Silva, et al.
Published: (2006-06-01)

Pure Erythroid Leukemia in a Sickle Cell Patient Treated with Hydroxyurea
by: Dhiraj Kumar Yadav, et al.
Published: (2020-07-01)

Sickle Cell Anemia Treatment With Hydroxyurea in Low-Resource Settings: Challenges and Opportunities for Global North-South Collaboration
by: Teresa S. Latham
Published: (2025-01-01)

Influence of ?S-globin haplotypes and hydroxyurea on tumor necrosis factor-alpha levels in sickle cell anemia
by: Marília Rocha Laurentino, et al.
Published: (2014-04-01)

Impact of hydroxyurea on clinical and biological parameters of sickle cell anemia in children in Abidjan
by: MIREILLE YAYO- AYE, et al.
Published: (2024-02-01)

The use of hydroxycarbamide in children with sickle cell anemia
by: Hafsat Rufai Ahmad, et al.
Published: (2018-01-01)

Protective effect of flavonoids against reactive oxygen species production in sickle cell anemia patients treated with hydroxyurea
by: Railson Henneberg, et al.
Published: (2013-01-01)

Mutagenicity of hydroxyurea in lymphocytes from patients with sickle cell disease
by: Khayat André Salim, et al.
Published: (2004-01-01)

Hydroxyurea therapy for neurological and cognitive protection in pediatric sickle cell anemia in Uganda (BRAIN SAFE II): Protocol for a single-arm open label trial
by: Vincent Mboizi, et al.
Published: (2024-12-01)

Hydroxyurea usage awareness among patients with sickle‐cell disease in Saudi Arabia
by: Mortadah Alsalman, et al.
Published: (2021-12-01)

Hydroxyurea granules for the management of sickle cell disease in children
by: Grace Lovia Allotey-Babington, et al.
Published: (2022-07-01)

Evaluation of the concentration of malondialdehyde and nitrite in patients with sickle cell anemia treated or not with hydroxyurea
by: Darcielle Bruna Dias Elias, et al.
Published: (2010-12-01)

Evaluation of the concentration of malondialdehyde and nitrite in patients with sickle cell anemia treated or not with hydroxyurea
by: Darcielle Bruna Dias Elias, et al.
Published: (2010-12-01)

Low Uptake of Hydroxyurea among a Cohort of Sickle Cell Disease Patients in Nigeria
by: Helen Chioma Okoye, et al.
Published: (2024-06-01)

Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil
by: Ana Cristina Silva-Pinto, et al.

Health-related quality of life of adolescents with sickle cell disease on hydroxyurea: A case-control study
by: Hayfaa Mohammed Mones, et al.
Published: (2022-01-01)

Adherence to Hydroxyurea and Patients’ Perceptions of Sickle Cell Disease and Hydroxyurea: A Cross-Sectional Study
by: Mohammed Ali Madkhali, et al.
Published: (2024-01-01)

Utilization of Hydroxyurea Among Patients Diagnosed with Sickle Cell Disease in Jazan, Saudi Arabia
by: Gohal GA, et al.
Published: (2022-11-01)

Optical laser trapping for studying the deformability of sickle red blood cells in response to hydroxyurea
by: Anmar A Hussein, et al.
Published: (2018-01-01)

Association of laboratory markers and cerebral blood flow among sickle cell anemia children
by: Corynne Stéphanie Ahouéfa Adanho, et al.
Published: (2022-08-01)

Atrial septal defect closure on cardiopulmonary bypass in a sickle cell anemia: Role of hydroxyurea and partial exchange transfusion
by: Gosavi Kundan, et al.
Published: (2010-01-01)

Caregivers’ Perceived Threat Of Sickle Cell Disease Complications And Its Association With Hydroxyurea Use Among Children With Sickle Cell Disease In Dar Es Salaam, Tanzania
by: Ally M, et al.
Published: (2024-12-01)

Sickle Cell Anaemia with Antiglobulin Positive Autoimmune Haemolytic Crisis
by: Saniya Khan, et al.
Published: (2023-09-01)

Influence of Oxidative Stress Biomarkers and Genetic Polymorphisms on the Clinical Severity of Hydroxyurea-Free Senegalese Children with Sickle Cell Anemia
by: Fatou Gueye Tall, et al.
Published: (2020-09-01)

Hydroxyurea and blood transfusion therapy for Sickle cell disease in South Asia: inconsistent treatment of a neglected disease
by: Thamal Darshana, et al.
Published: (2021-03-01)

Impact of Hydroxyurea to Treat Haematological Disorders on Male Fertility: Two Case Reports and a Systematic Review
by: Simone Cilio, et al.
Published: (2024-07-01)